# A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.

> **NCT01179594** · PHASE4 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** entecavir
- **DRUG:** peginterferon alfa-2a [Pegasys]
- **DRUG:** peginterferon alfa-2a [Pegasys]
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01179594
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-09-18
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was canceled for operational reasons.
- **Last updated:** 2017-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01179594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01179594, "A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT01179594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*